May 28, 2020Open Access

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients. Peripheral edema was the main toxic effect of grade 3 or higher. (Funded by Merck Darmstadt, Germany; VISION ClinicalTrials.gov number, NCT02864992.).

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Key Points

Abstract

Cite This Study